FDA opted not to fight a court order requiring it to award Depomed Inc.’s Gralise (gabapentin) seven years of orphan drug market exclusivity. But the agency is not changing its policy on orphan exclusivity: a sponsor will still have to show its product is clinically superior to the same previously approved drug in order to win the designation.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?